Status:
COMPLETED
Feasibility Study of the Hemolung Respiratory Assist System
Lead Sponsor:
Alung Technologies
Conditions:
Hypercapnic Respiratory Failure, COPD
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the Hemolung Respiratory Assist System in patients with hypercapnic respiratory failure associated with acute exacerbation of chroni...
Eligibility Criteria
Inclusion
- Moderate or severe COPD, as defined by the GOLD criteria
- Acute exacerbation of COPD (sustained worsening of patient's condition necessitating a change in regular medication)
- On non-invasive positive pressure mechanical ventilation \> 1hour with either:
- PaCO2 \> 55 mmHg with pH \< 7.25 OR
- PaCO2 \> 55 mmHg with \< 5mmHg decrease from baseline and pH \< 7.30
- Not severely hypoxemic (PaO2/FiO2 ≥ 200 mmHg on PEEP/CPAP ≤ 5 cmH2O)
- Hemodynamically stable (mean arterial pressure \> 65 mmHg without vasopressor support)
- Chronic arrhythmias (e.g., atrial fibrillation) well controlled
- Minimum platelet count of 100,000/mm3
- Minimum red blood cell count of 2.5 mill/μl
Exclusion
- Presence of acute, uncontrolled arrhythmia
- Acute ischemic heart disease
- Presence of bleeding diathesis
- Significant abnormality or weakness/paralysis of respiratory muscles due to a know muscular dystrophy or neurologic disorder
- Recent (\< 7 days) prolonged (\>24 hrs) use of muscle paralyzing agents
- Cerebrovascular accident, intracranial bleed, head injury or other neurologic disorder likely to affect ventilation
- Coma from any cause, or decreased consciousness
- Hypersensitivity to heparin or previous heparin induced thrombocytopenia
- Recent (\< 6 months) major chest abdominal trauma or surgery
- Presence of septic shock
- Presence of a significant pneumothorax or bronchopleural fistula
- History of uncontrolled major psychiatric disorder
- Pregnant women
- Known to have AIDS or to have symptomatic HIV
- Received chemotherapy or radiation within the previous 90 days
- Received an organ transplant other than corneal transplants
- Received or currently receiving immunosuppressive therapy, excluding corticosteroids within the last 3 months
- Presence of severe renal or liver failures
- Known vascular abnormality with could complicate or prevent successful insertion of the vascular access catheter in the right femoral vein
- Presence of another catheter in the right femoral vein that cannot be moved
- Presence of an inferior vena cava filter
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00987740
Start Date
October 1 2009
End Date
August 1 2010
Last Update
August 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Artemis Health Institute
Gurgaon, Haryana, India, 122001